Review Article

Volume – 1, Issue-1, 2025
Journal home Page: https://farpublisher.com/farjams/
Page: 14-19
Publication Month: Feb.2025

OPEN ACCESS

Immunological Challenges in HIV-Positive Sickle Cell Anemia Patients: A Narrative Review

By

Emmanuel Ifeanyi Obeagu[1] and Priya Homa Chukwu[2]

[1]Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, ORCID: 0000-0002-4538-0161
[2]Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science, Rivers State University of Science and Technology, Port Harcourt, Rivers State, Nigeria, ORCID: 0000-0002-1538-2924

Abstract

HIV-positive individuals with sickle cell anemia (SCA) face unique immunological challenges due to the combined effects of viral-induced immune suppression and chronic inflammation associated with SCA. HIV depletes CD4+ T cells, impairing adaptive immunity, while SCA promotes persistent immune activation through hemolysis, endothelial dysfunction, and cytokine overproduction. Together, these conditions exacerbate immune dysregulation, increasing susceptibility to infections, immune exhaustion, and inflammatory complications. The coinfection of HIV and SCA alters innate and adaptive immune responses, leading to defective neutrophil and monocyte function, suboptimal vaccine responses, and an increased risk of opportunistic infections. Functional asplenia in SCA further compromises the ability to clear encapsulated bacteria, making bacterial infections a significant concern. Additionally, HIV-induced dysregulation of B and T cell function impairs antibody responses, further reducing immune protection. These compounded effects create significant clinical and therapeutic challenges in managing infections and inflammation in affected individuals.

Keywords:* *HIV, Sickle Cell Anemia, Immunological Dysfunction, Co infection, Inflammation

Introduction

HIV and sickle cell anemia (SCA) are two chronic conditions that significantly impact immune function, posing unique challenges when they coexist in the same individual. HIV, a retroviral infection, primarily targets CD4+ T cells, leading to progressive immunodeficiency and increased susceptibility to opportunistic infections. On the other hand, SCA is a genetic disorder characterized by chronic hemolysis, vaso-occlusive crises (VOC), and systemic inflammation, which also results in immune dysfunction. The combination of these two conditions creates a complex immunological landscape that influences disease progression, infection risk, and overall patient outcomes.[1-2] SCA is associated with chronic inflammation due to ongoing red blood cell destruction and endothelial dysfunction. Hemolysis releases free hemoglobin and heme, which promote oxidative stress and pro-inflammatory cytokine production. Additionally, functional asplenia—a hallmark of SCA—compromises the immune system's ability to clear encapsulated bacteria, increasing susceptibility to infections such as *Streptococcus pneumoniae* and *Haemophilus influenzae*. While hydroxyurea therapy has been shown to reduce VOC and inflammation, its interactions with HIV pathophysiology and antiretroviral therapy (ART) remain an area of ongoing investigation.[3-4] HIV-induced immunosuppression further exacerbates immune dysfunction in SCA patients by impairing T cell-mediated immunity. The virus directly depletes CD4+ T cells and disrupts normal cytokine signaling, reducing the body's ability to mount effective immune responses. Additionally, chronic immune activation, a feature of both HIV and SCA, can lead to immune exhaustion, further compromising the host's defense against infections. This dual burden of immunodeficiency and hyper inflammation complicates disease management and contributes to increased morbidity and mortality.[5-6]

The innate immune system is also significantly affected in individuals with HIV and SCA. Neutrophils, which play a critical role in infection control, exhibit altered function in both conditions. In SCA, neutrophils are hyper activated and adhere excessively to the endothelium, contributing to VOC. In contrast, HIV infection impairs neutrophil function, reducing their ability to respond to pathogens effectively. Similarly, monocyte dysfunction in both conditions leads to increased inflammation and impaired phagocytic activity, further exacerbating infection susceptibility.[7-8] B cell dysfunction is another key immunological consequence of HIV-SCA coinfection. HIV disrupts normal B cell maturation and impairs antibody production, leading to reduced vaccine efficacy and a weakened humeral response. SCA patients already demonstrate suboptimal antibody responses due to splenic dysfunction and chronic inflammation, making this population particularly vulnerable to infections. Ensuring adequate vaccination and monitoring for immune responses is crucial in optimizing care for these patients.[9-10] The therapeutic management of HIV-SCA coinfection presents several challenges. ART is essential for controlling HIV progression, but certain antiretrovirals, such as zidovudine, can exacerbate anemia, a major concern in SCA. Additionally, drug interactions between hydroxyurea and ART require careful monitoring. Infection prevention remains a priority, with prophylactic antibiotics, regular vaccinations, and malaria prophylaxis playing a critical role in reducing morbidity. Supportive care measures, including blood transfusions and anti-inflammatory agents, may provide additional benefits,

though their impact on long-term immune function in this population needs further research.[11-12]

Immunological Dysfunctions in HIV-SCA Coinfection

The coexistence of HIV and sickle cell anemia (SCA) creates a unique and complex immunological landscape characterized by both immunodeficiency and chronic inflammation. Each condition independently alters the function of the immune system, and their combined effects further compromise host defenses, increasing susceptibility to infections, immune exhaustion, and inflammatory complications. These dysfunctions affect both the innate and adaptive arms of the immune system, complicating disease progression and management.[13-14]

Innate Immune Dysfunctions

The innate immune system, which provides the first line of defense against infections, is significantly disrupted in HIV-SCA coinfection. Neutrophils, a key component of innate immunity, exhibit functional impairments in both conditions. In SCA, neutrophils are hyper activated, contributing to increased endothelial adhesion and vaso-occlusive crises (VOC). In contrast, HIV induces neutropenia and impairs neutrophil chemotaxis and phagocytosis, leading to a reduced ability to combat bacterial and fungal infections. This dual impact creates a paradox where neutrophils are both overactive in inflammation and dysfunctional in pathogen clearance.[15-16] Monocyte and macrophage dysfunction further exacerbates immune dysregulation. Chronic hemolysis in SCA leads to excessive free hemoglobin and heme release, which promote monocyte activation and a pro-inflammatory state. In HIV, monocytes serve as reservoirs for viral replication and contribute to persistent immune activation. This persistent activation leads to dysregulated cytokine production, increased oxidative stress, and impaired antigen presentation, all of which weaken the immune system's ability to mount effective responses against pathogens.[17-18] Dendritic cells, crucial for antigen presentation and initiating adaptive immune responses, are also impaired in HIV-SCA patients. HIV directly infects dendritic cells, reducing their ability to present antigens and activate T cells. Meanwhile, chronic inflammation in SCA alters dendritic cell function, leading to suboptimal immune surveillance and defective adaptive immune responses. These dysfunctions contribute to the increased incidence of bacterial, fungal, and viral infections observed in HIV-positive SCA patients.[19-20]

Adaptive Immune Dysfunctions

HIV profoundly affects adaptive immunity by depleting CD4+ T cells, impairing helper T cell function, and disrupting cytokine signaling. This depletion is particularly concerning in SCA patients, who already experience immune dysregulation due to chronic inflammation and splenic dysfunction. Functional asplenia in SCA compromises the clearance of encapsulated bacteria, such as *Streptococcus pneumoniae* and *Haemophilus influenzae*, making these individuals highly susceptible to life-threatening infections. The additional loss of CD4+ T cells in HIV exacerbates this vulnerability.[21-22] T cell exhaustion is another hallmark of HIV-SCA coinfection. Chronic immune activation, driven by both conditions, leads to the overexpression of inhibitory receptors such as PD-1 on T cells. This results in functional exhaustion, where T cells lose their ability to proliferate and mount effective immune responses. The combination of HIV-driven immune suppression and SCA-associated chronic inflammation creates an environment where immune responses are persistently activated yet ineffective, increasing the risk of opportunistic infections and inflammatory complications.[23-24] B cell dysfunction is also a significant concern in HIV-SCA patients. HIV disrupts normal B cell development and impairs antibody production, leading to reduced vaccine efficacy and an increased risk of bacterial infections. SCA patients already exhibit defective antibody responses due to splenic dysfunction, and HIV further compromises B cell memory formation. As a result, these patients may not develop adequate protective immunity from vaccinations, necessitating booster doses and alternative immunization strategies to optimize their protection.[25-26]

Cytokine Imbalance and Chronic Inflammation

A dysregulated cytokine environment is a defining feature of HIV-SCA coinfection. SCA promotes chronic inflammation through the persistent release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8), which contribute to endothelial dysfunction and VOC. HIV, on the other hand, induces immune activation through the persistent stimulation of inflammatory pathways, further amplifying cytokine production. This sustained inflammatory state leads to endothelial damage, increased vascular permeability, and heightened thrombosis risk, all of which contribute to disease complications.[27-28] Conversely, regulatory cytokines such as interleukin-10 (IL-10) are often upregulated in HIV to counteract excessive immune activation. However, this anti-inflammatory response can also suppress protective immune functions, impairing pathogen clearance and vaccine responses. The imbalance between pro-inflammatory and anti-inflammatory cytokines in HIV-SCA patients creates an immune environment that is both overactive in inflammation and inadequate in pathogen defense, complicating clinical management.[29-30]

Increased Susceptibility to Infections in HIV-SCA Co infection

The coexistence of HIV and sickle cell anemia (SCA) creates a profound immunological burden that significantly increases susceptibility to infections. Both conditions independently compromise the immune system through distinct mechanisms, and their combined effects further weaken host defenses, predisposing individuals to bacterial, viral, fungal, and parasitic infections. The impairment of both innate and adaptive immunity in HIV-SCA co infection results in recurrent and severe infections, often requiring aggressive medical intervention.[31-32]

Bacterial Infections

Patients with SCA are particularly vulnerable to bacterial infections due to functional asplenia, which impairs the clearance of encapsulated bacteria such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis*. The loss of splenic function in SCA leads to decreased production of opsonizing antibodies, reducing the

body's ability to clear bacterial pathogens efficiently. HIV further exacerbates this vulnerability by depleting CD4+ T cells, impairing macrophage function, and disrupting normal B cell responses. As a result, HIV-SCA co infected patients face an elevated risk of severe bacterial infections, including pneumonia, meningitis, and sepsis.[33-34]

Viral Infections

The immunosuppressive effects of HIV increase susceptibility to opportunistic viral infections, including cytomegalovirus (CMV), Epstein-Barr virus (EBV), and varicella-zoster virus (VZV). These infections can manifest with severe complications, such as CMV retinitis and EBV-driven lymph proliferative disorders. Additionally, HIV impairs the immune response to viral infections that are common in SCA patients, such as parvovirus B19, which can cause aplastic crises due to its direct effect on erythroid progenitor cells. The combined impact of HIV-induced immunodeficiency and the hematological instability of SCA makes viral infections more severe and difficult to manage.[35-36]

Fungal and Parasitic Infections

HIV-SCA co infected individuals are at increased risk of fungal infections, including candidiasis, cryptococcosis, and invasive aspergillosis. HIV-related immune suppression, particularly the loss of CD4+ T cells, impairs the body's ability to control fungal pathogens. Additionally, chronic hemolysis and iron overload in SCA create a favorable environment for fungal growth, further predisposing these patients to severe fungal infections.[37-38] Malaria is another major concern in regions where SCA and HIV are prevalent. Although individuals with SCA exhibit some resistance to *Plasmodium falciparum* infection due to altered red blood cell morphology, severe malaria remains a significant risk, particularly in HIV-positive patients. HIV impairs the immune response to malaria, increasing parasite burden and the likelihood of severe complications, such as cerebral malaria and severe anemia. The interaction between HIV, SCA, and malaria represents a critical public health challenge, necessitating targeted preventive and therapeutic strategies.[39-40]

Impaired Vaccine Responses

Vaccine-preventable infections are a major concern in HIV-SCA patients due to impaired humoral immunity. SCA patients have suboptimal vaccine responses due to splenic dysfunction, while HIV further reduces vaccine efficacy by impairing B cell maturation and antibody production. As a result, routine vaccinations, including pneumococcal, meningococcal, and influenza vaccines, may provide inadequate protection. Booster doses and alternative immunization strategies, such as conjugate vaccines and adjuvanted formulations, may be necessary to enhance immune responses in this population.[41]

Clinical Implications and Management Strategies

The increased susceptibility to infections in HIV-SCA patients necessitates proactive management strategies, including early initiation of ART to preserve immune function, prophylactic antibiotics to prevent bacterial infections, and antifungal and antimalarial prophylaxis in endemic regions. Regular vaccination, combined with close monitoring for breakthrough infections, is essential for reducing morbidity and mortality.[42]

Therapeutic and Management Challenges in HIV-SCA Coinfection

Managing HIV and sickle cell anemia (SCA) concurrently presents significant therapeutic challenges due to the complex interactions between the two conditions. The need for lifelong antiretroviral therapy (ART), the complications associated with SCA, and the heightened risk of infections create a unique clinical scenario that requires a multidisciplinary approach. Several factors, including drug interactions, treatment adherence, and the impact of both diseases on organ function, complicate the effective management of these patients.[43]

Challenges in Antiretroviral Therapy (ART) Administration

The cornerstone of HIV management is ART, which effectively suppresses viral replication and preserves immune function. However, administering ART in HIV-SCA coinfected patients is challenging due to potential drug interactions, altered pharmacokinetics, and side effects. SCA patients often require medications such as hydroxyurea for disease management, which may interact with certain ART regimens. For instance, hydroxyurea, which increases fetal hemoglobin production and reduces vaso-occlusive crises (VOC), has been associated with bone marrow suppression, a side effect that can be exacerbated by nucleoside reverse transcriptase inhibitors (NRTIs) like zidovudine. Careful selection of ART regimens is necessary to minimize hematologic toxicity and ensure effective viral suppression.[44]

Management of Vaso-Occlusive Crises and Pain

Pain management in SCA is critical, particularly during VOC episodes. However, opioid-based analgesics, commonly used for VOC pain, may have immunosuppressive effects, which could further compromise HIV-infected patients. Additionally, chronic opioid use increases the risk of drug dependency, adding another layer of complexity to treatment. Non-opioid pain management strategies, including nonsteroidal anti-inflammatory drugs (NSAIDs), physiotherapy, and cognitive-behavioral approaches, should be considered to minimize opioid-related complications while effectively managing pain.[45]

Increased Risk of Organ Damage

Both HIV and SCA independently contribute to organ dysfunction, but their combined effects significantly increase the risk of complications affecting multiple organ systems. Chronic hemolysis in SCA leads to endothelial dysfunction, which, when combined with HIV-associated inflammation, increases the risk of cardiovascular diseases, nephropathy, and pulmonary hypertension. HIV-associated nephropathy (HIVAN) is particularly concerning in SCA patients, as renal dysfunction is already a common complication of the disease. Regular monitoring of kidney function and careful selection of ART drugs with minimal nephrotoxic effects, such as tenofovir, are essential in preventing further renal damage. Hepatic dysfunction is another major concern due to the increased risk of viral hepatitis co-infections, iron overload from repeated blood

transfusions, and ART-related hepatotoxicity. Liver function tests should be routinely monitored, and iron chelation therapy should be considered in patients with significant iron overload.[46]

Infection Prevention and Management

HIV-SCA coinfected patients are at an increased risk of infections due to their compromised immune systems. Preventing infections requires a combination of prophylactic antibiotics, antifungal therapy, and regular vaccinations. However, immune dysfunction in both diseases can lead to suboptimal vaccine responses, necessitating alternative immunization strategies, such as conjugate vaccines and booster doses. Furthermore, malaria remains a major challenge in endemic regions. Although SCA provides partial resistance to *Plasmodium falciparum*, HIV impairs immune responses, increasing the severity of malaria infections. Antimalarial prophylaxis, combined with mosquito control strategies, should be prioritized to reduce the burden of malaria in HIV-SCA patients.[47]

Adherence and Psychosocial Barriers

Adherence to lifelong treatment regimens poses a significant challenge for patients with HIV-SCA coinfection. The high pill burden, frequent hospital visits, and the chronic nature of both conditions can lead to treatment fatigue, reducing adherence to ART and SCA medications. Mental health support, counseling, and community-based interventions can improve adherence and overall health outcomes. Additionally, stigma associated with both HIV and SCA can create social and psychological barriers to seeking care, highlighting the need for patient-centered approaches that address these challenges.[48]

The Need for Multidisciplinary Care

Given the complexity of managing HIV-SCA coinfection, a multidisciplinary approach is essential. A coordinated team involving hematologists, infectious disease specialists, nephrologists, pain management experts, and mental health professionals can help optimize treatment strategies and improve patient outcomes. Further research into novel therapeutic interventions, such as gene therapy for SCA and long-acting ART formulations, may provide better treatment options in the future.[48]

Conclusion

The coexistence of HIV and sickle cell anemia (SCA) presents significant immunological, therapeutic, and management challenges that require a comprehensive and multidisciplinary approach. The compounded effects of both diseases lead to heightened immune dysfunction, increased susceptibility to infections, and a greater risk of organ damage, necessitating careful and individualized patient care. Understanding the complex interactions between HIV and SCA is essential for developing effective treatment strategies that minimize complications and improve patient outcomes. Despite advancements in antiretroviral therapy (ART) and sickle cell disease management, several challenges persist, including drug interactions, suboptimal vaccine responses, and the increased risk of vaso-occlusive crises and end-organ damage. Addressing these challenges requires tailored therapeutic strategies that balance the benefits and risks of ART and SCA-specific treatments, along with proactive infection prevention measures. Additionally, adherence to long-term treatment regimens remains a critical issue, requiring enhanced patient education, psychosocial support, and innovative treatment delivery approaches to improve compliance.

References

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The interaction between sickle cell disease and HIV infection: a systematic review. Clinical Infectious Diseases. 2015; 60(4):612-626.
2. Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis. Transfusion Medicine Reviews. 2019; 33(3):162-169.
3. Ola B, Olushola O, Ebenso B, Berghs M. Sickle Cell Disease and Its Psychosocial Burdens in Africa. InSickle Cell Disease in Sub-Saharan Africa 2024: 67-80. Routledge.
4. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. Sickle cell disease: new opportunities and challenges in Africa. The scientific world journal. 2013; 2013(1):193252.
5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Frontiers in Pediatrics. 2020; 8:38.
6. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology, 2024; 2(1): 14-33
7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61
9. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024; 10(1):25-36.
10. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Asian J Dental Health Sci, 2024; 4(1):32-7. Available from: http://ajdhs.com/index.php/journal/article/view/62
11. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
12. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17

13. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73 1
14. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20- 35
15. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIVExposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Newport International Journal of Biological and Applied Sciences (NIJBAS) 2023. http://hdl.handle.net/20.500.12493/14626
17. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. Circulation. 2023; 147(1):83-100.
18. Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circulation research. 2024; 134(11):1515-1545
19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, Titanji BK, Hileman CO, Bagchi S. Inflammatory and immune mechanisms for atherosclerotic cardiovascular disease in HIV. International journal of molecular sciences. 2024; 25(13):7266..
20. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
21. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, Loureiro P, Máximo C, de Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infectious Diseases. 2020; 20(1):638.
23. Bhowmik A, Banerjee P. Hematological manifestation in HIV infected children. J Coll Physicians Surg Pak. 2015; 25(2):119-123.
24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. Hematologic abnormalities associated with simian immunodeficieny virus (SIV) infection mimic those in HIV infection. Journal of Medical Primatology. 2012; 41(3):214-224.
25. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study. Sexually transmitted infections. 2012; 88(7):528-533.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024; 2(1):33-45.
27. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
28. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
29. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
30. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIVPositive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
31. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies . Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
32. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
33. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
34. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
35. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
36. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
37. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy. 2015; 12:1-8.
38. Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. BMC hematology. 2014; 14:1-7.

39. Gudina A, Wordofa M, Urgessa F. Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. Plos one. 2024; 19(10):e0310239.
40. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities and associated factors among HIV infected children pre-and post-antiretroviral treatment, North West Ethiopia. Journal of blood medicine. 2017:99-105.
41. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. PLoS One. 2017; 12(3):e0174233.
42. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024; 2(4):68-85.
43. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
44. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, Balama M, Tembo D, Gondwe J, Orlando S, Palombi L, Marazzi MC. Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS One. 2020; 15(11):e0242068.
45. Ashenafi G, Tibebu M, Tilahun D, Tsegaye A. Immunohematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, Borana, Ethiopia. Journal of Blood Medicine. 2023:543-554.
46. Obeagu EI, Goryacheva OG. The Role of Inflammation in HIV and Sickle Cell Disease Co-Morbidity. Lifeline HIV, 2025; 3(1): 1-12
47. Obeagu EI, Goryacheva OG. Oxidative Stress in HIV and Sickle Cell Disease: A Double Burden. Lifeline HIV, 2025; 3(1): 13-24
48. Obeagu EI, Goryacheva OG. HIV and Sickle Cell Disease: A Focus on Liver Dysfunction. Lifeline HIV, 2025; 3(1): 25-40.

